Switzerland· 66652001
Prevymis 240 mg, Filmtabletten
A letermovir product containing letermovirum, registered in Switzerland by MSD Merck Sharp & Dohme AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Letermovir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX18 (letermovir), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Letermovir · ATC J05AX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of letermovir costs, country by country.
Normalised to the WHO defined daily dose (0.48 g), the median price runs from $9.77 in France to $563.69 in Italy — a ×58 gap.
- Switzerland: $371.41 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Letermovir · price per daily dose (0.48 g)
USD · FX 28 Sept 2026
- IT Italy$563.69
- CH Switzerland$371.41
- FR France$9.77
The record
At a glance
Swissmedic (Switzerland)- Active substance
- letermovirum
- Manufacturer
- MSD Merck Sharp & Dohme AG
- Country
- Switzerland (CH)
- ATC code
- J05AX18
- ATC class
- Letermovir
- Defined daily dose
- 0.48 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768066652001728 StkCHF 4228.65
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
222 interactions on record for letermovir.
Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Letermovir · interactions on record
222 records
- 38 severe
- 172 moderate
- 12 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- CilostazolB01AC23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Letermovir in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPREVYMISOrifarm Oy
- CzechiaPREVYMISMerck Sharp & Dohme B.V., Haarlem
- SpainPREVYMIS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Sharp & Dohme B.V.
- FrancePREVYMIS 240 mg, comprimé pelliculéMERCK SHARP & DOHME (PAYS-BAS)
- IcelandPrevymisMerck Sharp & Dohme B.V.*
- NetherlandsPrevymis 240 mg, filmomhulde tablettenMerck Sharp & Dohme B.V.
- NorwayPrevymisMerck Sharp & Dohme B.V. (1)
- PolandPrevymisMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Prevymis
- Liechtenstein · Prevymis
- Norway · Prevymis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/92cf28fa-9c49-4673-bf80-7099e338bca7 GET /v1/drugs/92cf28fa-9c49-4673-bf80-7099e338bca7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "letermovirum 240 mg",
"valid_from": "2020-11-01",
"limitations": "[{\"description\":\"<b>CMV-Prophylaxe bei Empfängern eines hämatopoetischen Stammzelltransplantats (HSZT)</b><br>\\nPrevymis ist indiziert zur Prophylaxe von Cytomegalovirus-(CMV)-Infektionen oder -Erkrankungen bei Erwachsenen und für alle pädiatrische Patienten mit einem Gewicht von mindestens 30 kg und für pädiatrische Patienten mit einem Gewicht von 15 kg bis unter 30 kg für eine Verabreichung ohne Ciclosporin, die CMV-seropositive Empfänger R+ eines allogenen hämatopoetischen Stammzelltransplantats sind.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: Indikationscode: 20765.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"20765.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-04-01\"},{\"description\":\"<b>CMV-Prophylaxe bei Nierentransplantatempfängern (nur für 240 mg Filmtabletten und 480 mg Filmtabletten)</b><br>\\nProphylaxe der CMV-Erkrankung bei Erwachsenen und Jugendlichen ab dem Alter von 12 Jahren und mit einem Körpergewicht von mindestens 40 kg, die Nierentransplantatempfänger mit hohem Risiko (CMV-seropositiver Spender/CMV-seronegativer Empfänger D+/R-) sind.<br>\\n<br>\\nMSD Merck Sharp & Dohme AG erstattet nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin jede bezogene Packung PREVYMIS ORAL einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 20765.02<br>\\n<br>\",\"costApproval\":null,\"indication\":\"20765.02\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-01-01\",\"validTo\":\"2028-12-31\"}]",
"galenic_form": "Filmtabl 240 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2019-01-01",
"self_retention_pct": 10
}See everything about letermovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.